Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients

Vicente Soriano1, Juan Berenguer

  • 1aHospital Universitario La Paz bInstituto de Investigación Sanitaria La Paz cHospital General Universitario Gregorio Marañón dInstituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

Insights

HIV and hepatitis C virus (HCV) coinfection accelerates liver fibrosis. Extrahepatic manifestations of HCV are common in coinfected patients and may be reduced by antiviral therapy.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Immunology

Background:

  • HIV infection accelerates hepatitis C virus (HCV)-related liver fibrosis, increasing risks of cirrhosis and liver decompensation.
  • Extrahepatic manifestations of HCV significantly contribute to morbidity and mortality in chronic hepatitis C patients.
  • HCV primarily targets the liver, but its systemic effects are increasingly recognized.

Purpose of the Study:

  • To review current data on extrahepatic comorbidities associated with HCV in HIV-infected patients.
  • To understand the impact of HCV on non-liver related conditions in coinfected individuals.

Main Methods:

  • Literature review of current data on extrahepatic manifestations in HIV/HCV coinfection.
  • Analysis of studies examining comorbidities in coinfected populations.

Main Results:

  • A significant proportion of HIV/HCV coinfected individuals exhibit extrahepatic manifestations.
  • These manifestations include autoimmune disorders, lymphoproliferative diseases, and cardiovascular, renal, metabolic, and CNS issues.
  • Chronic immune activation and systemic inflammation in both HIV and HCV contribute to these comorbidities.

Conclusions:

  • Extrahepatic manifestations of HCV represent a substantial burden of morbidity and mortality in coinfected patients.
  • Successful antiviral therapy leading to HCV eradication may reduce both hepatic and extrahepatic manifestations.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
46
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.4K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
748